RedHill Biopharma (RDHL) investor relations material

Company overview and business model

• Specialty biopharmaceutical company focused on GI, infectious diseases, medical countermeasures, and oncology, aiming to become a leading specialty biopharma firm.

• Commercializes Talicia® in the U.S. through a joint venture with Cumberland and has out-licensed products for territories outside the U.S.

• Pipeline includes five clinical-stage therapeutic candidates, with a focus on in-licensing or acquiring products with high therapeutic and commercial potential.

• Plans to commercialize candidates via licensing, partnerships, or independent operations, evaluating co-development and co-promotion on a case-by-case basis.

Financial performance and metrics

• Preliminary estimated net revenues for 2025 are $6.5–$7.5 million, down from $8.0 million in 2024.

• Estimated cash, cash equivalents, and short-term investments as of December 31, 2025, are approximately $4.1 million.

• As of June 30, 2025, pro forma as adjusted total shareholders' equity is $37.4 million, with total capitalization of $37.4 million.

Use of proceeds and capital allocation

• No proceeds from the resale of ADSs by the selling shareholder; proceeds from exercise of pre-funded warrants will be used for general corporate purposes.

• No current intention to pay cash dividends; earnings will be reinvested in business development and expansion.